Targeting the cell cycle and the PI3K pathway: A possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 873-881

  David Pfeuty, Thérèse ^a   Legraverend, Michel ^a   Ludwig, Odile ^a   Grierson, David S ^a  

^a INSTITUT CURIE   (France)

Author keywords

Anticancer strategy; Cell cycle; Cell growth; Cyclin dependent kinase; p53; Phosphatidyl inositol 3 kinase; Rb

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; INDIRUBIN 3' MONOXIME; MAMMALIAN TARGET OF RAPAMYCIN; MITOMYCIN C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PURINE; PURINE DERIVATIVE; PURVALANOL A; RAPAMYCIN; RETINOBLASTOMA PROTEIN; ROSCOVITINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL KILLING; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LETHALITY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; CHROMONES; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR STRUCTURE; MORPHOLINES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PURINES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77749299398     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000565     Document Type: Article

References (39)

1. Lowe SW, Cepero E and Evan G: Intrinsic tumor suppression. Nature 432: 307-315, 2004.
2. Sherr CJ and McCormick F: The Rb and p53 pathways in cancer. Cancer Cell 2: 103-112, 2002.
3. Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869, 1999.
4. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
5. Hardcastle IR, Golding BT and Griffin RJ: Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol 42: 325-348, 2002.
6. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783, 2006.
7. Day Y and Grant S: Small molecule inhibitors targeting cyclindependent kinases as anticancer agents. Curr Oncol Rep 6: 123-130, 2004.
8. Phillips AC and Vousden K: E2F-1 dependent apoptosis. Apoptosis 6: 173-182, 2001.
9. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N, Inagaki M, Delcros J-G and Moulinoux J-P: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536, 1997.
10. David-Pfeuty T: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18: 7409-7422, 1999.
11. David-Pfeuty T, Nouvian-Dooghe Y, Sirri V, Roussel P and Hernandez-Verdun D: Common and reversible regulation of wild-type p53 function and ribosomal biogenesis by protein kinases in human cells. Oncogene 20: 5951-5963, 2001.
12. Ruggero D and Pandolfi PP: Does the ribosome translate cancer? Nat Rev Cancer 3: 179-192, 2003.
13. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
14. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 93-105, 2002.
15. Legraverend M, Ludwig O, Leclerc S and Meijer L: Synthesis of a new series of purine derivatives and their anti-cyclindependent kinase activities. J Heterocyclic Chem 38: 299-303, 2001.
16. Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L and Endicott J: Cyclindependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J Med Chem 43: 1282-1292, 2000.
17. Ducrot P, Legraverend M and Grierson DS: D-QSAR CoMFA on cyclin-dependent kinase inhibitors. J Med Chem 43: 4098-4108, 2003.
18. Fischer PM: The use of Cdk inhibitors in oncology: a pharmacological perspective. Cell Cycle 3: 742-746, 2004.
19. Mgbonyebi OP, Russo J and Russo IH: Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 15: 1903-1910, 1999.
20. Edamatsu H, Gau C-L, Nemoto T, Guo L and Tamanoi F: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cells. Oncogene 19: 3059-3068, 2000.
21. Somerville L and Cory JG: Enhanced roscovitine-induced apoptosis is mediated by a caspase-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Anticancer Res 20: 3347-3355, 2000.
22. Mihara M, Shintani S, Kiyota A, Matsumura T and Wong DT: Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous carcinoma cells. Int J Oncol 21: 95-101, 2002.
23. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P and Grant S: The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 63: 1822-1833, 2003.
24. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringhausen I, Fend F, Pescel, C and Decker T: Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18: 747-755, 2004.
25. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fisher PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D and Lane D: In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (roscovitine). Int J Cancer 102: 463-468, 2002.
26. Gray NS, Wodicka L, Thunnissen A-MWH, Norman, TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim S-H, Lockhart DJ and Schultz PG: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533-538, 1998.
27. Hoessel R, Leclerc S, Endicott JA, Nobel MEN, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G and Meijer L: Indirubin, the active constituent of a chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1: 60-67, 1999.
28. David-Pfeuty T: The flexible evolutionary anchorage-dependent Pardee's restriction point of mammalian cells. How its deregulation may lead to cancer. BBA-Rev Cancer 1765: 38-66, 2006.
29. Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3ß regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511, 1998.
30. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514, 2000.
31. Boxer LM and Dang CV: Translocations involving c-myc and c-myc functions. Oncogene 20: 5595-5610, 2001.
32. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
33. Pardee AB and James LJ: Selective killing of transformed baby hamster kidney (BHK) cells. Proc Natl Acad Sci USA 72: 4994-4998, 1975.
34. Glickman MH and Raveh D: Proteasome plasticity. FEBS Lett 579: 3214-3223, 2005.
35. Lipinski MM and Jacks T: The retinoblastoma gene family in differentiation and development. Oncogene 18: 7873-7882, 1999.
36. Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG and Mani S: Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 1: 695-706, 2002.
37. Knight ZA and Shokat KM: Features of selective kinase inhibitors. Chem Biol 12: 621-637, 2005.
38. Polychronopoulos P, Magiatis P, Skaltsounis A-L, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P and Meijer L: Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 47: 935-946, 2004.
39. Liu H, Dibling B, Spike B, Dirlam A and Macleod K: New roles for the Rb tumor suppressor protein. Curr Opin Genet Dev 14: 55-64, 2004.